Archives

Loading Events

Biomarkers In Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Biomarkers In Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Background

Clinical complications associated with autosomal polycystic kidney disease (ADPKD) appear gradually over time and are associated with the progressive development of cysts, kidney enlargement, and loss of renal function.1 The clinical course of ADPKD is marked by a long course of stable kidney function, despite the relentless expansion of kidney volume due to the growth of cysts.1 Height adjusted total kidney volume (Ht-TKV) has been recognized as a prognostic biomarker of cyst burden and disease severity.2 Can biomarker data provide additional information to improve prognostication for patients with ADPKD? Is it possible to create a biomarker profile to phenotype patients with ADPKD?

Did You Know?
  • Tubular secretory clearance may be compromised before detectable changes in GFR in patients with ADPKD.3
Why Attend This Webinar?
  • In this cutting-edge webinar, we will discuss the most current data on biomarkers in ADPKD, focusing on those that are most validated in the literature.
What You Will Learn
  • The different types of biomarkers (i.e., urine, serum, etc.) and how they can be utilized to understand ADPKD progression
  • Key biomarkers associated with prognostication and how these biomarkers might be used to evaluate ADPKD disease progression
  • Current gaps in the literature and potential next steps for future research in ADPKD biomarkers will be discussed
References
  1. Halvorson CR et al. Int J Nephrol Renovasc Dis. 2010; 3: 69-83.
  2. Irazabal MV et al. JASN. 2015; 26: 160-172.
  3. Wang K et al. CJASN. 2020; 15: 80–88.

Featuring

Pranav Garimella

Pranav Garimella, MBBS, MPH, FASN

Assistant Professor of Medicine

University of California San Diego*

Dr. Pranav Garimella is board-certified nephrologist and assistant professor and director of the dialysis outreach program in the department of medicine and nephrology at UC San Diego. He received his training in India, Chicago, and completed his fellowship at Tufts University, training in clinical nephrology with a focus on polycystic kidney disease with Dr. Ron Perrone. His research endeavors have led to multiple NIH-funded studies and numerous peer-reviewed publications on the topic of kidney diseases. He has an ongoing NIH grant for his research elucidating aspects of kidney disease and has been the recipient of a multitude of teaching and clinical excellence awards. He is also involved in initiatives to develop programs specifically targeted at minority populations in an effort to improve health literacy and potentially clinical outcomes.

Kelly Reed

Kelly Reed, PhD

Nephrology Senior Clinical & Scientific Liaison

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Kelly Reed, PhD, joined Otsuka in 2012 and is currently a Senior Clinical & Scientific Liaison on our Nephrology East Team. Dr Reed has collaborated with several national professional organizations and healthcare systems providing educational presentations on hyponatremia and Autosomal Dominant Polycystic Kidney Disease (ADPKD). She has been a leader in resource development for the MSL team, co-led the nephrology MSL new hire training program during expansion and served as a mentor to several MSL new hires. Dr Reed earned her doctorate from Virginia Commonwealth University in Richmond, Virginia and completed her clinical internship at the Mailman Center for Child Development in Miami, Florida, followed by a two year fellowship at Cincinnati Children’s Hospital Medical Center.

Marla Dallal

Marla Dallal, PharmD, RPH

Nephrology Clinical & Scientific Liaison

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Marla Dallal, PharmD, RPH is a Clinical & Scientific Liaison at Otsuka Pharmaceutical Development and Commercialization covering Southern California. She earned her Doctor of Pharmacy degree from the University of Southern California, School of Pharmacy in Los Angeles. While in pharmacy school, Dr Dallal pursued various clinical internships within the acute care and ambulatory care settings at Cedars-Sinai Medical Center and Kaiser Permanente. Prior to joining Otsuka, Dr Dallal held various positions within Medical Affairs at Amgen Inc covering the cardiometabolic and nephrology therapeutic areas. She also served as a preceptor at Amgen Inc, where she instructed pharmacy students on Advanced Pharmacy Practice rotations. She is currently licensed as a pharmacist in the state of California with the National Association Board of Pharmacy.

*Dr Garimella is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Drs Reed and Dallal are employees of OPDC.

Registration

Please Log In Or Join to Register for this Event.

Related Resources